z-logo
open-access-imgOpen Access
201 A Re-audit of Lignocaine 5% Medicated Plaster (Versatis®) Prescribing in an Older Adult Inpatient Population Following Changes to Reimbursement Provisions
Author(s) -
Deirdre McCartan,
Alison Poff,
Stuart Lee,
Alan Martin
Publication year - 2019
Publication title -
age and ageing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.014
H-Index - 143
eISSN - 1468-2834
pISSN - 0002-0729
DOI - 10.1093/ageing/afz103.120
Subject(s) - medicine , medical prescription , audit , pharmacy , reimbursement , formulary , population , physical therapy , analgesic , emergency medicine , family medicine , anesthesia , health care , nursing , management , environmental health , economics , economic growth
Background Lignocaine 5% medicated plasters (Versatis®) are licensed only for treatment of postherpetic neuralgia. Our 2017 audit of Versatis® prescribing recorded a potential cost of €28,297/year for just 26 patients, all off-label. We noted however the limited choice of analgesics in older adults due to co-morbid conditions such as CKD and frailty. The 2017 Medicines Management Programme (MMP) directive for label-only Versatis® prescribing aimed to reduce annual exchequer costs of €30 million noting 25,000 people had prescriptions under Community Drugs Schemes (CDS) in 2016. Methods We conducted a re-audit of Versatis® prescribing on five core geriatric medical, orthogeriatric and rehabilitation wards across three inpatient sites. Indication for, duration of and patient's personal view of the plaster was recorded. Pharmacy provided medications costings. Cost per day and per length of stay were calculated. All other prescribed analgesics were recorded. Results Analgesics prescribed for 127 patients were recorded. Mean age was 81 years, 63% female. 4/127(3%) were prescribed Versatis® compared to 26/129(20%) in 2017, all off-label.Indications included osteoarthritis and spinal stenosis. All four patients were prescribed the plaster prior to admission. Cost per plaster was €3.46 compared to €2.58 in 2017. Cost of Versatis® for these 4 admissions was €346 for their combined 100 bed days. Total cost of co-prescribed paracetamol for these four patients was €45.90. Three patients noted little analgesic benefit, one felt the plaster a psychological support. Seventeen different analgesics were prescribed across 127 kardexes. Conclusion No patient was newly prescribed Versatis® during their admission. The MMP directive for the prescribing of Versatis® influenced prescribing practice across our hospital sites. Community practice for prescribing off-label is still evident for chronic pain, reflecting the difficulty of pain control in older adults. The cost of individual plasters increased by 0.88€ since 2017.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom